IP Library Granted Patent US 8,940,289
Granted Patent B2
US 8,940,289 · App. 13/428,776 · Granted Jan 27, 2015

Fusion molecules and IL-15 variants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,940,289
App. No.
13/428,776
Granted
Jan 27, 2015
Kind
B2
Abstract

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Claims (8)

1. A method of stimulating immune responses in a mammal comprising administering to the mammal an effective amount of an isolated human interleukin 15 (hIL-15) variant comprising an amino acid substitution at position 72 of a mature hIL-15 sequence, wherein the amino acid substitution results in an hIL-15 variant that has IL-15 agonist activity and increased binding activity for the IL-15 receptor beta/gamma chain (IL-15RβγC) receptors compared to the native hIL-15 polypeptide.

2. The method of claim 1 , wherein the isolated hIL-15 variant comprises an amino acid substitution of N to D at position 72 of the mature human IL-15 sequence.

3. The method of claim 2 , wherein said binding activity of said hIL-15 variant for the IL-15RβγC receptors is increased by at least 3-fold compared to the native hIL-15 polypeptide.

4. The method of claim 2 , wherein said hIL-15 variant increases proliferation of an IL15R-bearing cell compared to the native hIL-15 polypeptide.

5. The method of claim 4 , wherein said IL15R-bearing cell comprises a T cell, and wherein said IL-15 variant increases proliferation of said T cell by at least 3-fold compared to the native hIL-15 polypeptide.

6. The method of claim 1 , wherein said mammal is a human.

7. The method of claim 1 , wherein said mature hIL-15 sequence consists of the amino acid sequence set forth in SEQ ID NO: 1.

8. The method of claim 1 , wherein the isolated hIL-15 variant comprises an amino acid substitution of N to A at position 72 of the mature human IL-15 sequence.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
MERGER AND CHANGE OF NAME Recorded Sep 4, 2019
From: ALTOR BIOSCIENCE CORPORATION; ALTOR BIOSCIENCE LLC
To: ALTOR BIOSCIENCE LLC
Reel/Frame 050260/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2013
From: WONG, HING C.; RHODE, PETER; ZHU, XIAOYUN; HAN, KAI-PING
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 030929/0837 →